The novel DNA alkylating agent BO-1090 suppresses the growth of human oral cavity cancer in xenografted and orthotopic mouse models

International Journal of Cancer

Volumn 130, Issue 6, 2012, Pages 1440-1450

  Sanjiv, Kumar ^a,b,c   Su, Tsann Long ^c,d   Suman, Sharda ^c   Kakadiya, Rajesh ^c   Lai, Tsung Ching ^e   Wang, Hsuan Yao ^e   Hsiao, Michael ^e   Lee, Te Chang ^a,c  

^a ACADEMIA SINICA   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

^d CHINA MEDICAL UNIVERSITY   (Taiwan)

^e GENOMICS RESEARCH CENTER   (Taiwan)

Author keywords

anticancer; DNA interstrand crosslinks; human oral cancer; novel DNA alkylating agent; orthotopic mouse models; xenografted

Indexed keywords

ALKYLATING AGENT; ANTINEOPLASTIC AGENT; BO 1090; BO 1100; BO 1130; BO 1131; CISPLATIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BLOOD CELL COUNT; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE PROGRESSION; CONTROLLED STUDY; DNA DAMAGE; DNA SYNTHESIS INHIBITION; DOUBLE STRANDED DNA BREAK; DRUG CYTOTOXICITY; DRUG SENSITIVITY; DRUG STRUCTURE; G1 PHASE CELL CYCLE CHECKPOINT; GENE INDUCTION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; MOUTH CANCER; NONHUMAN; PRIORITY JOURNAL; S PHASE CELL CYCLE CHECKPOINT; SINGLE STRANDED DNA BREAK; TUMOR XENOGRAFT;

ALKYLATING AGENTS; ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CELL CYCLE CHECKPOINTS; CELL GROWTH PROCESSES; CELL LINE; CELL LINE, TUMOR; CHO CELLS; CRICETINAE; DNA; DNA DAMAGE; FIBROBLASTS; G1 PHASE; HUMANS; KB CELLS; MICE; MOUTH NEOPLASMS; S PHASE;

EID: 84856079543     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.26142     Document Type: Article

References (39)

1. Warnakulasuriya S,. Living with oral cancer: epidemiology with particular reference to prevalence and life-style changes that influence survival. Oral Oncol 2010; 46: 407-10.
2. Petersen PE,. Oral cancer prevention and control-the approach of the World Health Organization. Oral Oncol 2009; 45: 454-60.
3. Caballero M, Grau JJ, Casellas S, Bernal-Sprekelsen M, Blanch JL,. The role of chemotherapy in advanced oral cavity cancer. Acta Otorrinolaringol Esp 2009; 60: 260-7.
4. Andreadis C, Vahtsevanos K, Sidiras T, Thomaidis I, Antoniadis K, Mouratidou D,. 5-Fluorouracil and cisplatin in the treatment of advanced oral cancer. Oral Oncol 2003; 39: 380-5. (Pubitemid 36379346)
5. van der Wall E, Beijnen JH, Rodenhuis S,. High-dose chemotherapy regimens for solid tumors. Cancer Treat Rev 1995; 21: 105-32.
6. Verweij J, Pinedo HM,. Mitomycin C: mechanism of action, usefulness and limitations. Anticancer Drugs 1990; 1: 5-13.
7. Helleday T, Petermann E, Lundin C, Hodgson B, Sharma RA,. DNA repair pathways as targets for cancer therapy. Nat Rev Cancer 2008; 8: 193-204. (Pubitemid 351301852)
8. Hall MD, Handley MD, Gottesman MM,. Is resistance useless? Multidrug resistance and collateral sensitivity. Trends Pharmacol Sci 2009; 30: 546-56.
9. Cui B, Johnson SP, Bullock N, Ali-Osman F, Bigner DD, Friedman HS,. Bifunctional DNA alkylator 1,3-bis(2-chloroethyl)-1-nitrosourea activates the ATR-Chk1 pathway independently of the mismatch repair pathway. Mol Pharmacol 2009; 75: 1356-63.
10. Levin VA, Silver P, Hannigan J, Wara WM, Gutin PH, Davis RL, Wilson CB,. Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report. Int J Radiat Oncol Biol Phys 1990; 18: 321-4. (Pubitemid 20097526)
11. Kapuriya N, Kapuriya K, Dong H, Zhang X, Chou TC, Chen YT, Lee TC, Lee WC, Tsai TH, Naliapara Y, Su TL,. Novel DNA-directed alkylating agents: design, synthesis and potent antitumor effect of phenyl N-mustard-9-anilinoacridine conjugates via a carbamate or carbonate linker. Bioorg Med Chem 2009; 17: 1264-75.
12. Kapuriya N, Kapuriya K, Zhang X, Chou TC, Kakadiya R, Wu YT, Tsai TH, Chen YT, Lee TC, Shah A, Naliapara Y, Su TL,. Synthesis and biological activity of stable and potent antitumor agents, aniline nitrogen mustards linked to 9-anilinoacridines via a urea linkage. Bioorg Med Chem 2008; 16: 5413-23. (Pubitemid 351694491)
13. Kakadiya R, Dong H, Lee PC, Kapuriya N, Zhang X, Chou TC, Lee TC, Kapuriya K, Shah A, Su TL,. Potent antitumor bifunctional DNA alkylating agents, synthesis and biological activities of 3a-aza-cyclopenta[a]indenes. Bioorg Med Chem 2009; 17: 5614-26.
14. Chang JY, Chang CY, Kuo CC, Chen LT, Wein YS, Kuo YH,. Salvinal, a novel microtubule inhibitor isolated from Salvia miltiorrhizae Bunge (Danshen), with antimitotic activity in multidrug-sensitive and -resistant human tumor cells. Mol Pharmacol 2004; 65: 77-84.
15. Kaina B, Fritz G, Mitra S, Coquerelle T,. Transfection and expression of human O6-methylguanine-DNA methyltransferase (MGMT) cDNA in Chinese hamster cells: the role of MGMT in protection against the genotoxic effects of alkylating agents. Carcinogenesis 1991; 12: 1857-67.
16. Yang JL, Hsieh FP, Lee PC, Tseng HJ,. Strand- and sequence-specific attenuation of N-methyl-N'-nitro-N-nitrosoguanidine-induced G.C to A.T transitions by expression of human 6-methylguanine-DNA methyltransferase in Chinese hamster ovary cells. Cancer Res 1994; 54: 3857-63.
17. Lee PC, Kakadiya R, Su TL, Lee TC,. Combination of bifunctional alkylating agent and arsenic trioxide synergistically suppresses the growth of drug-resistant tumor cells. Neoplasia 2010; 12: 376-87.
18. Babich H, Reisbaum AG, Zuckerbraun HL,. In vitro response of human gingival epithelial S-G cells to resveratrol. Toxicol Lett 2000; 114: 143-53. (Pubitemid 30125451)
19. Lai KC, Chang KW, Liu CJ, Kao SY, Lee TC,. IFN-induced protein with tetratricopeptide repeats 2 inhibits migration activity and increases survival of oral squamous cell carcinoma. Mol Cancer Res 2008; 6: 1431-9.
20. D'Incalci M, Colombo T, Ubezio P, Nicoletti I, Giavazzi R, Erba E, Ferrarese L, Meco D, Riccardi R, Sessa C, Cavallini E, Jimeno J, et al. The combination of yondelis and cisplatin is synergistic against human tumor xenografts. Eur J Cancer 2003; 39: 1920-6. (Pubitemid 37311190)
21. Shalinsky DR, Bischoff ED, Gregory ML, Lamph WW, Heyman RA, Hayes JS, Thomazy V, Davies PJ,. Enhanced antitumor efficacy of cisplatin in combination with ALRT1057 (9-cis retinoic acid) in human oral squamous carcinoma xenografts in nude mice. Clin Cancer Res 1996; 2: 511-20. (Pubitemid 26100052)
22. Norrgren K, Sjolin M, Bjorkman S, Areberg J, Johnsson A, Johansson L, Mattsson S,. Comparative renal, hepatic, and bone marrow toxicity of cisplatin and radioactive cisplatin (191Pt) in Wistar rats. Cancer Biother Radiopharm 2006; 21: 528-34. (Pubitemid 44747609)
23. Bonner WM, Redon CE, Dickey JS, Nakamura AJ, Sedelnikova OA, Solier S, Pommier Y,. GammaH2AX and cancer. Nat Rev Cancer 2008; 8: 957-67.
24. Thurston DE,. Nucleic acid targeting: therapeutic strategies for the 21st century. Br J Cancer 1999; 80 (Suppl 1): 65-85. (Pubitemid 29389611)
25. Wong E, Giandomenico CM,. Current status of platinum-based antitumor drugs. Chem Rev 1999; 99: 2451-66.
26. McHugh PJ, Spanswick VJ, Hartley JA,. Repair of DNA interstrand crosslinks: molecular mechanisms and clinical relevance. Lancet Oncol 2001; 2: 483-90. (Pubitemid 33586303)
27. Konopa J,. G2 block induced by DNA crosslinking agents and its possible consequences. Biochem Pharmacol 1988; 37: 2303-9.
28. Dronkert ML, Kanaar R,. Repair of DNA interstrand cross-links. Mutat Res 2001; 486: 217-47. (Pubitemid 32763210)
29. Thurston DE, Bose DS, Thompson AS, Howard PW, Leoni A, Croker SJ, Jenkins TC, Neidle S, Hartley JA, Hurley LH,. Synthesis of sequence-selective C8-linked Pyrrolo[2,1-c][1,4]benzodiazepine DNA interstrand cross-linking agents. J Org Chem 1996; 61: 8141-7. (Pubitemid 26400930)
30. Barlogie B, Drewinko B,. Lethal and cytokinetic effects of mitomycin C on cultured human colon cancer cells. Cancer Res 1980; 40: 1973-80. (Pubitemid 10116123)
31. Bergerat JP, Barlogie B, Gohde W, Johnston DA, Drewinko B,. In vitro cytokinetic response of human colon cancer cells to cis- dichlorodiammineplatinum(II). Cancer Res 1979; 39: 4356-63. (Pubitemid 10197588)
32. Mailand N, Falck J, Lukas C, Syljuasen RG, Welcker M, Bartek J, Lukas J,. Rapid destruction of human Cdc25A in response to DNA damage. Science 2000; 288: 1425-9. (Pubitemid 30366329)
33. Ota I, Ohnishi K, Takahashi A, Yane K, Kanata H, Miyahara H, Ohnishi T, Hosoi H,. Transfection with mutant p53 gene inhibits heat-induced apoptosis in a head and neck cell line of human squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2000; 47: 495-501. (Pubitemid 30236393)
34. Pabla N, Huang S, Mi QS, Daniel R, Dong Z,. ATR-Chk2 signaling in p53 activation and DNA damage response during cisplatin-induced apoptosis. J Biol Chem 2008; 283: 6572-83.
35. Chehab NH, Malikzay A, Appel M, Halazonetis TD,. Chk2/hCds1 functions as a DNA damage checkpoint in G(1) by stabilizing p53. Genes Dev 2000; 14: 278-88. (Pubitemid 30106483)
36. Matsuoka S, Huang M, Elledge SJ,. Linkage of ATM to cell cycle regulation by the Chk2 protein kinase. Science 1998; 282: 1893-7. (Pubitemid 28555269)
37. Passagne I, Evrard A, Depeille P, Cuq P, Cupissol D, Vian L,. O(6)-methylguanine DNA-methyltransferase (MGMT) overexpression in melanoma cells induces resistance to nitrosoureas and temozolomide but sensitizes to mitomycin C. Toxicol Appl Pharmacol 2006; 211: 97-105. (Pubitemid 43238303)
38. Nissen-Meyer R, Host H,. A comparison between the hematological side effects of cyclophosphamide and nitrogen mustard. Cancer Chemother Rep 1960; 9: 51-5.
39. Mullins GM, Colvin M,. Intensive cyclophosphamide (NSC-26271) therapy for solid tumors. Cancer Chemother Rep 1975; 59: 411-9.